Ping Chi, MD, PhD
Affiliations: | Memorial Sloan Kettering Cancer Center, Rockville Centre, NY, United States | ||
| Rockefeller University, New York, NY, United States |
Area:
transcriptional regulation by oncogenic factorsWebsite:
https://www.mskcc.org/research-areas/labs/ping-chiGoogle:
"Ping Chi"Parents
Sign in to add mentor| Paul Greengard | grad student | 2001 | Rockefeller | |
| (Synapsin dynamics and function in living hippocampal synapses.) | ||||
| Timothy A. Ryan | grad student | 2001 | Rockefeller (Neurotree) | |
| (Synapsin dynamics and function in living hippocampal synapses.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Janku F, Abdul Razak AR, Chi P, et al. (2020) Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000522 |
| Blay JY, Serrano C, Heinrich MC, et al. (2020) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology |
| Francis JH, Diamond EL, Chi P, et al. (2020) MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocular Oncology and Pathology. 6: 159-163 |
| Kelly CM, Antonescu CR, Bowler T, et al. (2020) Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. Jama Oncology |
| George S, Heinrich MC, Zalcberg JR, et al. (2020) Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Journal of Clinical Oncology. 38: 11539-11539 |
| Heinrich MC, George S, Zalcberg JR, et al. (2020) Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Journal of Clinical Oncology. 38: 11535-11535 |
| Antonescu CR, Dickson BC, Swanson D, et al. (2019) Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. The American Journal of Surgical Pathology |
| Rosenbaum E, Kelly C, D'Angelo SP, et al. (2019) A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. The Oncologist |
| Kelly CM, Chi P, Dickson MA, et al. (2019) A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Journal of Clinical Oncology. 37: 11049-11049 |
| Rosenbaum E, Jonsson P, Seier K, et al. (2019) DNA damage response pathway alterations and clinical outcome in leiomyosarcoma. Journal of Clinical Oncology. 37: 11048-11048 |